Donors who have received an experimental drug, agent, or vaccine, and who are referred for a research plasma or leukocyte collection specifically because they were given this drug, agent, or vaccine, are acceptable if their research product is collected for use only by the PI who administered the experimental drug, agent or vaccine. Otherwise, they are deferred for one year after receiving an experimental drug, agent, or vaccine.